Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06914908 · ClinicalTrials.gov registry record · Phase 2
Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study
A Phase 2 study of Chronic Rhinosinusitis With Nasal Polyps, sponsored by Sanofi.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 64
- Enrollment target
- 20
- Study locations
NCT06914908 is a Phase 2 study of Chronic Rhinosinusitis With Nasal Polyps that is actively recruiting participants, run by Sanofi. The registered enrollment target is 64 participants, below the 137-participant average among 11 other Chronic Rhinosinusitis With Nasal Polyps trials with a reported enrollment target (53% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT06914908, a Phase 2 study of Chronic Rhinosinusitis With Nasal Polyps, is actively recruiting participants, sponsored by Sanofi.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 64 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a single-arm extension study to investigate the long-term safety, tolerability, and efficacy of lunsekimig in adult participants with inadequately controlled CRSwNP who have completed a previous lunsekimig CRSwNP clinical study (also referred to as the parent study ACT18207). The study duration will be up to approximately 56 weeks per participant, 52 weeks of treatment period, and 4 weeks of follow-up.
Conditions Studied
Interventions
- DRUG Mometasone furoate nasal spray (MFNS)
- DRUG lunsekimig
Study Locations (20)
Other
- Investigational Site Number : 0320001 - Buenos Aires
- Investigational Site Number : 0320003 - Mendoza
- Investigational Site Number : 0560002 - Ghent
- Investigational Site Number : 0560001 - Leuven
- Investigational Site Number : 1000001 - Sofia
- Investigational Site Number : 8260003 - Manchester
- Investigational Site Number : 8260001 - Newcastle upon Tyne
Texas
- McGovern Medical School - UT Physicians Dermatology - Bellaire Station- Site Number : 8400017 - Bellaire
- Pharmaceutical Research & Consulting- Site Number : 8400004 - Dallas
- ENT Associates of Texas - McKinne- Site Number : 8400014 - McKinney
- Alamo ENT Associates- Site Number : 8400001 - San Antonio
California
- Modena Allergy + Asthma- Site Number : 8400005 - La Jolla
Idaho
- Treasure Valley Medical Research- Site Number : 8400002 - Boise
Oklahoma
- Essential Medical Research- Site Number : 8400020 - Tulsa
Santa Fe Province
- Investigational Site Number : 0320002 - Rosario
Greater Poland Voivodeship
- Investigational Site Number : 6160004 - Poznan
Lesser Poland Voivodeship
- Investigational Site Number : 6160002 - Krakow
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2025-05-12 |
| Est. Completion | 2031-01-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06914908
The ClinicalTrials.gov registry entry for NCT06914908 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 137-participant average among 11 other Chronic Rhinosinusitis With Nasal Polyps trials with a reported enrollment target (53% lower). The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Rhinosinusitis With Nasal Polyps appearing as the primary indexed condition, and to 2 interventions - of which Mometasone furoate nasal spray (MFNS) is the first listed.
NCT06914908 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Texas, California.
Frequently Asked Questions
What is clinical trial NCT06914908 about?
NCT06914908 is a clinical study titled "Long-term Safety and Efficacy Evaluation of Lunsekimig in Adult Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Study". This is a single-arm extension study to investigate the long-term safety, tolerability, and efficacy of lunsekimig in adult participants with inadequately controlled CRSwNP who have completed a previous lunsekimig CRSwNP clinical study (also referred to as the parent study ACT18207). The study dura...
What is the current status of trial NCT06914908?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2025-05-12. Estimated completion is 2031-01-29.
What conditions does trial NCT06914908 study?
This clinical trial studies the following conditions: Chronic Rhinosinusitis With Nasal Polyps.
What interventions are being tested in trial NCT06914908?
The interventions under investigation include: Mometasone furoate nasal spray (MFNS) (DRUG), lunsekimig (DRUG).
Who is sponsoring clinical trial NCT06914908?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06914908 being conducted?
This trial has 20 study locations across California, Idaho, Oklahoma, Texas, Santa Fe Province. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Rhinosinusitis With Nasal Polyps
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps
ACTIVE NOT RECRUITING · Phase 2
-
A Phase 3 Study to Assess the Efficacy, Safety, and Tolerability of Itepekimab (Anti-IL-33 mAb) in Participants With Inadequately-controlled Chronic Rhinosinusitis With Nasal Polyps
RECRUITING · Phase 3
-
The Role of IL5 in Epithelial Cell Integrity
RECRUITING · Early Phase 1
-
A Study to Investigate Changes in Symptoms in Adult Participants With Chronic Rhinosinusitis With Nasal Polyposis Initiating Treatment With Tezepelumab
RECRUITING · Phase 3
-
3D Printing to Improve Nasal Irrigation Outcome
RECRUITING · NA
-
Dupilumab Treatment Effects in an Ethnically Diverse Population With Chronic Rhinosinusitis With Nasal Polyposis
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.